Back to top
more

Ocular Therapeutix (OCUL)

(Delayed Data from NSDQ)

$4.65 USD

4.65
3,887,451

-0.36 (-7.10%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $4.64 -0.01 (-0.11%) 4:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround

by Zacks Equity Research

Ocular Therapeutix (OCUL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 34.7% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0% and 3.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Can VAALCO (EGY) Deliver Strong Q4 Earnings Performance?

by Zacks Equity Research

While lower commodity prices are likely to have hurt VAALCO Energy's (EGY) Q4 bottom line, an impressive production profile might somewhat aid results.

Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings?

by Zacks Equity Research

Ocular Therapeutix (OCUL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Are You Looking for a Top Momentum Pick? Why Ocular Therapeutix (OCUL) is a Great Choice

by Zacks Equity Research

Does Ocular Therapeutix (OCUL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 64.63%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 64.6% in Ocular Therapeutix (OCUL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Does Ocular Therapeutix (OCUL) Have the Potential to Rally 134.83% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 134.8% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Why Ocular Therapeutix (OCUL) Stock Might be a Great Pick

by Zacks Equity Research

Ocular Therapeutix (OCUL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Verve Therapeutics (VERV) Surges 28.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

Verve Therapeutics (VERV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 6.90% and 3.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 14.71% and 3.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Stevanato Group (STVN) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Stevanato (STVN) delivered earnings and revenue surprises of 7.14% and 0.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Avita Medical Inc. (RCEL): Can Its 20.4% Jump Turn into More Strength?

by Zacks Equity Research

Avita Medical Inc. (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -14.81% and 4.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

What Makes Ocular Therapeutix (OCUL) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Ocular Therapeutix (OCUL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 4% and 3.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Chinook Therapeutics (KDNY) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Chinook (KDNY) delivered earnings and revenue surprises of -13.92% and 28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

IsoRay (ISR) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

IsoRay (ISR) delivered earnings and revenue surprises of -100% and 56.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Moves 35.1% Higher: Will This Strength Last?

by Zacks Equity Research

Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised)

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -30.43% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.